MCID: VSC018
MIFTS: 37

Visceral Steatosis

Categories: Rare diseases, Liver diseases

Aliases & Classifications for Visceral Steatosis

MalaCards integrated aliases for Visceral Steatosis:

Name: Visceral Steatosis 53 55
Fatty Metamorphosis of Viscera 53 73
Fatal Neonatal Hepatic Steatosis 53
White Liver Disease 53
Steatosis of Liver 53
Steatohepatitis 73

Classifications:



External Ids:

Summaries for Visceral Steatosis

MalaCards based summary : Visceral Steatosis, also known as fatty metamorphosis of viscera, is related to visceral steatosis, congenital and azoospermia. An important gene associated with Visceral Steatosis is SLC22A5 (Solute Carrier Family 22 Member 5), and among its related pathways/superpathways are AMP-activated Protein Kinase (AMPK) Signaling and AMPK Enzyme Complex Pathway. The drugs Zinc and Pioglitazone have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and heart.

Related Diseases for Visceral Steatosis

Diseases in the Visceral Steatosis family:

Visceral Steatosis, Congenital

Diseases related to Visceral Steatosis via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 visceral steatosis, congenital 12.1
2 azoospermia 9.8
3 fatty liver disease 9.8
4 carnitine palmitoyltransferase i deficiency 9.3 CPT1A CPT1B
5 carnitine palmitoyltransferase ii deficiency, infantile 9.2 CPT1A CPT1B
6 body mass index quantitative trait locus 11 9.0 CPT1A CPT1B

Graphical network of the top 20 diseases related to Visceral Steatosis:



Diseases related to Visceral Steatosis

Symptoms & Phenotypes for Visceral Steatosis

Drugs & Therapeutics for Visceral Steatosis

Drugs for Visceral Steatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 432)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4,Phase 2,Not Applicable 7440-66-6 23994
2
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 111025-46-8 4829
3
Amlodipine Approved Phase 4 88150-42-9 2162
4
Simvastatin Approved Phase 4,Not Applicable 79902-63-9 54454
5
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
6
Ribavirin Approved Phase 4,Phase 3,Not Applicable 36791-04-5 37542
7
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
8
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
9
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 7439-89-6 23925
10
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
11
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
12
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
13
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
14
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
15
Ethanol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 64-17-5 702
16
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Not Applicable 122320-73-4 77999
17
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
18
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
19
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
20
Peginterferon alfa-2a Approved, Investigational Phase 4,Not Applicable 198153-51-4 5360545
21
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
22
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
23
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
24
Menthol Approved Phase 4,Not Applicable 2216-51-5 16666
25
Selenium Approved, Investigational, Vet_approved Phase 4 7782-49-2
26
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754
27
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
28
Rifampicin Approved Phase 4,Phase 1 13292-46-1 5458213 5381226
29
Gliclazide Approved Phase 4 21187-98-4 3475
30
Cortisone acetate Approved, Investigational Phase 4 1950-04-4, 50-04-4 5745
31
Tamoxifen Approved Phase 4 10540-29-1 2733526
32
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
33
Efavirenz Approved, Investigational Phase 4,Not Applicable 154598-52-4 64139
34
Benzocaine Approved, Investigational Phase 4,Phase 3,Not Applicable 1994-09-7, 94-09-7 2337
35
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
36
Empagliflozin Approved Phase 4,Phase 3,Not Applicable 864070-44-0
37
Insulin Aspart Approved Phase 4 116094-23-6 16132418
38
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
39
Insulin Detemir Approved Phase 4 169148-63-4 5311023
40
Rifaximin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 80621-81-4 6436173
41
Racepinephrine Approved Phase 4,Phase 2 329-65-7 838
42
Glimepiride Approved Phase 4 93479-97-1 3476
43
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
44
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
45
Saxagliptin Approved Phase 4 361442-04-8 11243969
46
Methionine Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 63-68-3 6137
47
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 1406-16-2
48
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2 65-23-6 1054
49
Choline Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 62-49-7 305
50
Tocopherol Approved, Investigational, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1406-66-2 14986

Interventional clinical trials:

(show top 50) (show all 924)
# Name Status NCT ID Phase Drugs
1 Complex Imaging Assessment of Steatosis Unknown status NCT02669641 Phase 4
2 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4 entecavir;entecavir;essentiale + entecavir;Vitamin E + entecavir
3 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
4 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
5 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
6 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
7 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4 Losartan + Simvastatin;Amlodipine + Simvastatin
8 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
9 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
10 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
11 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
12 Endobarrier Treatment in Obese Subjects With T2DM Unknown status NCT01718457 Phase 4
13 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4 Valsartan;Hydrochlorothiazide
14 Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy Unknown status NCT02652884 Phase 4 phosphate and betamethasone acetate, 2 mL.;saline 0.9% NaCl
15 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4 Exenatide
16 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4 Exenatide
17 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4 Xenical, Pegasys, Copegus
18 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4 Metformin;Metformin
19 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4 Pioglitazone study drug;Placebo;Pioglitazone Open Label
20 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4 Pioglitazone;Placebo
21 Efficacy Study of Liraglutide vs.Sitagliptin vs. Glargine on Liver Fat in T2DM Subjects Completed NCT02147925 Phase 4 Liraglutide combined with metformin;Insulin glargine combined with metformin;Sitagliptin combined with metformin
22 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4 pioglitazone-placebo;pioglitazone;pioglitazone-placebo;Vitamin E-placebo
23 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4 Orlistat (Xenical)
24 Effects of Ipragliflozin on Excessive Fat in Type 2 Diabetes Patients With Non-alcoholic Fatty Liver Disease Treated With Metformin and Pioglitazone Completed NCT02875821 Phase 4 Ipragliflozin;metformin with pioglitazone
25 Changes in Liver Steatosis After Switching to Raltegravir in HIV/HCV Coinfection Completed NCT01900015 Phase 4 Raltegravir;Efavirenz
26 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4 Liraglutide;Metformin;Gliclazide
27 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4 Long-acting bedtime insulin detemir (Levemir);Insulin detemir and pre-meal insulin aspart.
28 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4 Vitamin D3;placebo
29 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4 Anastrozole;Tamoxifen
30 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4 Oral administration of Lobeglitazone
31 Impact of Short-term Fructose-enriched Diet on Serum Metabolome by Normal- and Over-weighed Women. Completed NCT03444233 Phase 4
32 The Effects of PXR Activation on Hepatic Fat Content Completed NCT02329405 Phase 4 Rifampicin;Placebo
33 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Completed NCT01761318 Phase 4 Liraglutide;Liraglutide - Placebo
34 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4 Triptorelin
35 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4 Pioglitazone;Placebo Oral Tablet
36 Use of Metformin in Treatment of Childhood Obesity Completed NCT02274948 Phase 4 Metformin;Placebo
37 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
38 Response of Individuals With Ataxia-Telangiectasia to Metformin and Pioglitazone Completed NCT02733679 Phase 4 Metformin;Pioglitazone
39 Lactate Metabolism Study in HIV Infected Persons Completed NCT00202228 Phase 4 cofactor supplementation (thiamine, riboflavin, L-carnitine)
40 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4 sodium phenylbutyrate;Placebo
41 A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth Completed NCT00755547 Phase 4
42 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients of South Asian Descent Completed NCT02660047 Phase 4 Liraglutide;Liraglutide - Placebo
43 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed NCT01505673 Phase 4 Liraglutide;Saline
44 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4 KRG (Korea Red ginseng);Placebo (for KRG)
45 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4 Ribavirin;Peginterferon alfa-2a;Ribavirin;Peginterferon alfa-2a
46 SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies Completed NCT01744236 Phase 4 Liraglutide;Sitagliptin;Exenatide;Liraglutide placebo;Sitagliptin placebo;Exenatide placebo;L-NMMA
47 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Completed NCT02277587 Phase 4 Plenadren;Conventional glucocorticoid therapy
48 Exenatide Compared With Insulin Glargine to Change Liver Fat Content in Type 2 Diabetes Recruiting NCT02303730 Phase 4 Exenatide;insulin glargine
49 SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD Recruiting NCT02649465 Phase 4 Tofogliflozin;Glimepiride
50 Effects of Combined Dapagliflozin and Exenatide Versus Dapagliflozin and Placebo on Ectopic Lipids in Patients With Uncontrolled Type 2 Diabetes Mellitus. Recruiting NCT03007329 Phase 4 Exenatide;Exenatide matching Placebo;Dapagliflozin

Search NIH Clinical Center for Visceral Steatosis

Genetic Tests for Visceral Steatosis

Anatomical Context for Visceral Steatosis

MalaCards organs/tissues related to Visceral Steatosis:

41
Liver, Testes, Heart, Endothelial, Kidney, Bone, Brain

Publications for Visceral Steatosis

Articles related to Visceral Steatosis:

(show all 33)
# Title Authors Year
1
Failure of the feeding response to fasting in carnitine-deficient juvenile visceral steatosis (JVS) mice: involvement of defective acyl-ghrelin secretion and enhanced corticotropin-releasing factor signaling in the hypothalamus. ( 19744557 )
2009
2
Expression and distribution of OCTN2 in mouse epididymis and its association with obstructive azoospermia in juvenile visceral steatosis mice. ( 16734862 )
2006
3
Attenuation of cardiac hypertrophy in carnitine-deficient juvenile visceral steatosis (JVS) mice achieved by lowering dietary lipid. ( 16452314 )
2006
4
Identification of the up- and down-regulated genes in the heart of juvenile visceral steatosis mice. ( 15056854 )
2004
5
Functional disorders of the oxidative phosphorylation system in the heart mitochondria of mice with juvenile visceral steatosis. ( 12612434 )
2003
6
Effect of gamma-butyrobetaine on fatty liver in juvenile visceral steatosis mice. ( 11341370 )
2001
7
Antagonizing effect of AP-1 on glucocorticoid induction of urea cycle enzymes: a study of hyperammonemia in carnitine-deficient, juvenile visceral steatosis mice. ( 11136545 )
2000
8
The signaling pathway of cardiotrophin-1 is not activated in hypertrophied ventricles of carnitine-deficient juvenile visceral steatosis (JVS) mice. ( 10904873 )
2000
9
Catecholamine metabolism inhibitors and receptor blockades only partially suppress cardiac hypertrophy of juvenile visceral steatosis mice with systemic carnitine deficiency. ( 10210276 )
1999
10
Dysfunctions of the epididymis as a result of primary carnitine deficiency in juvenile visceral steatosis mice. ( 10100867 )
1999
11
Pyruvate dehydrogenase kinase 4 mRNA is increased in the hypertrophied ventricles of carnitine-deficient juvenile visceral steatosis (JVS) mice. ( 10609898 )
1999
12
Decreased tissue distribution of L-carnitine in juvenile visceral steatosis mice. ( 10087008 )
1999
13
Loss of wild-type carrier-mediated L-carnitine transport activity in hepatocytes of juvenile visceral steatosis mice. ( 10498652 )
1999
14
Cardiomegaly in the juvenile visceral steatosis (JVS) mouse is reduced with acute elevation of heart short-chain acyl-carnitine level after L-carnitine injection. ( 10025944 )
1999
15
A missense mutation of mouse OCTN2, a sodium-dependent carnitine cotransporter, in the juvenile visceral steatosis mouse. ( 9837751 )
1998
16
Characteristics of cardiac hypertrophy in the juvenile visceral steatosis mouse with systemic carnitine deficiency. ( 9602426 )
1998
17
A novel gene suppressed in the ventricle of carnitine-deficient juvenile visceral steatosis mice. ( 9187371 )
1997
18
The effect of carnitine on ketogenesis in perfused livers from juvenile visceral steatosis mice with systemic carnitine deficiency. ( 9212045 )
1997
19
Suppressed expression of the urea cycle enzyme genes in the liver of carnitine-deficient juvenile visceral steatosis (JVS) mice in infancy and during starvation in adulthood. ( 9058209 )
1997
20
Secondary abnormality of carnitine biosynthesis results from carnitine reabsorptional system defect in juvenile visceral steatosis mice. ( 9540857 )
1997
21
Abnormal gene expression causing hyperammonemia in carnitine-deficient juvenile visceral steatosis (JVS) mice. ( 9286432 )
1997
22
Carnitine transport defect in fibroblasts of juvenile visceral steatosis (JVS) mouse. ( 8670273 )
1996
23
Disordered expression of glycolytic and gluconeogenic liver enzymes of juvenile visceral steatosis mice with systemic carnitine deficiency. ( 8858199 )
1996
24
Increased expression of carnitine palmitoyltransferase I gene is repressed by administering L-carnitine in the hearts of carnitine-deficient juvenile visceral steatosis mice. ( 8830050 )
1996
25
Altered expression of carnitine palmitoyltransferase II in liver, muscle, and heart of mouse strain with juvenile visceral steatosis. ( 8605222 )
1996
26
Mapping of jvs (juvenile visceral steatosis) gene, which causes systemic carnitine deficiency in mice, on chromosome 11. ( 7626891 )
1995
27
Mitochondrial abnormalities of muscle tissue in mice with juvenile visceral steatosis associated with systemic carnitine deficiency. ( 7773507 )
1995
28
Primary defect of juvenile visceral steatosis (jvs) mouse with systemic carnitine deficiency is probably in renal carnitine transport system. ( 8155735 )
1994
29
Cardiac hypertrophy in juvenile visceral steatosis (jvs) mice with systemic carnitine deficiency. ( 8325377 )
1993
30
Abnormal expression of urea cycle enzyme genes in juvenile visceral steatosis (jvs) mice. ( 1540663 )
1992
31
Proto-oncogene c-jun and c-fos messenger RNAs increase in the liver of carnitine-deficient juvenile visceral steatosis (jvs) mice. ( 1383034 )
1992
32
Carnitine administration to juvenile visceral steatosis mice corrects the suppressed expression of urea cycle enzymes by normalizing their transcription. ( 1544887 )
1992
33
Animal model of systemic carnitine deficiency: analysis in C3H-H-2 degrees strain of mouse associated with juvenile visceral steatosis. ( 1996978 )
1991

Variations for Visceral Steatosis

Expression for Visceral Steatosis

Search GEO for disease gene expression data for Visceral Steatosis.

Pathways for Visceral Steatosis

GO Terms for Visceral Steatosis

Cellular components related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrial outer membrane GO:0005741 8.62 CPT1A CPT1B

Biological processes related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 fatty acid metabolic process GO:0006631 9.26 CPT1A CPT1B
2 fatty acid beta-oxidation GO:0006635 9.16 CPT1A CPT1B
3 carnitine shuttle GO:0006853 8.96 CPT1A CPT1B
4 carnitine metabolic process GO:0009437 8.62 CPT1A SLC22A5

Molecular functions related to Visceral Steatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transferase activity, transferring acyl groups GO:0016746 8.96 CPT1A CPT1B
2 carnitine O-palmitoyltransferase activity GO:0004095 8.62 CPT1A CPT1B

Sources for Visceral Steatosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....